A New Jersey pharmaceutical company has voluntarily pulled thousands of bottles of a blood pressure medication off the market due to concerns it may have been cross-contaminated with a different drug, according to the U.S. Food and Drug Administration.
The recall involves more than 11,100 bottles of the combination tablet containing bisoprolol fumarate and hydrochlorothiazide, sold under the brand name Ziac. In testing of reserve lots, regulators found traces of ezetimibe, a medication used to lower cholesterol, the FDA reported.
This recall is classified as Class III, meaning that exposure to the product is not expected to cause serious health problems.
Glenmark Pharmaceuticals Inc., based in Elmwood Park, is conducting the recall of the medication, which comes in two strengths: 2.5 mg and 6.25 mg.
Affected packaging includes:
- 30-count bottles with NDC 68462-878-30
- 100-count bottles with NDC 68462-878-01
- 500-count bottles with NDC 68462-878-05
The affected lots have expiration dates spanning from November 2025 to May 2026.
For context, Class III recalls indicate a low likelihood of adverse health effects from exposure, but they still require action to prevent potential risk.
If you or someone you know has one of these bottles, consult a healthcare provider about alternatives and how to dispose of the product safely. See the FDA’s recall guidance for more details.
Tags: FDA, Glenmark Pharmaceuticals, high blood pressure, recall, Ziac
Copyright 2025 Nexstar Media Inc. All rights reserved.
